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ABSTRACT: Current chemotherapeutics for leishmaniasis have
multiple deficiencies, and there is a need for new safe, efficacious,
and affordable medicines. This study describes a successful drug
repurposing approach that identifies the over-the-counter antihist-
amine, clemastine fumarate, as a potential antileishmanial drug
candidate. The screening for inhibitors of the sphingolipid synthase
(inositol phosphorylceramide synthase, IPCS) afforded, following
secondary screening against Leishmania major (Lmj) promasti-
gotes, 16 active compounds. Further refinement through the dose
response against LmjIPCS and intramacrophage L. major amasti-
gotes identified clemastine fumarate with good activity and
selectivity with respect to the host macrophage. On target
engagement was supported by diminished sensitivity in a
sphingolipid-deficient L. major mutant (ΔLmjLCB2) and altered phospholipid and sphingolipid profiles upon treatment with
clemastine fumarate. The drug also induced an enhanced host cell response to infection indicative of polypharmacology. The activity
was sustained across a panel of Old and New World Leishmania species, displaying an in vivo activity equivalent to the currently used
drug, glucantime, in a mouse model of L. amazonensis infection. Overall, these data validate IPCS as an antileishmanial drug target
and indicate that clemastine fumarate is a candidate for repurposing for the treatment of leishmaniasis.
KEYWORDS: Leishmania, ceramide, sphingolipids, repurposing, IPCS, clemastine fumarate
Infecting over 1 billion people,1,2 neglected tropical diseases(NTDs) are a group of 20 diseases that are prevalent in
poorer populations of the world. These diseases are classified
as “neglected” due to both this predominance in areas of
poverty and their relatively low priority on national and
international health agendas.3 Causing an estimated 3.32
million disability adjusted life years (DALYs) and accounting
for 13% of all NTD DALYs,4,5 the leishmaniases are one of the
most widespread and serious of the NTDs.1,5−7
Caused by insect vector-borne kinetoplastid parasites of the
genus Leishmania, the leishmaniases are endemic in 98
countries, placing an estimated 310 million people at risk.
There are 1.3 million new cases recorded annually, and the
disease claims in excess of 30,000 lives each year.6
Leishmaniasis encompasses a range of clinical manifestations
that affect both humans and animals. There are three main
human disease states that are caused by 21 of the 30
Leishmania species that infect mammals.8 Cutaneous leishma-
niasis (CL), commonly caused by L. major, presents as
ulcerations that may heal spontaneously. In more extreme
cases, as with recurrent and diffuse cutaneous leishmaniasis,
these lesions are chronic and difficult to treat.2 Mucocutaneous
leishmaniasis (MCL) is the most disfiguring form involving the
destruction of buccopharyngeal tissue. While they are nonfatal,
CL and MCL can be extremely debilitating and can lead to
long-term stigma for those afflicted.9 Visceral leishmaniasis
(VL), the most severe form of leishmaniasis caused mainly by
L. donovani, manifests with fever, hepatosplenomegaly, and
pancytopenia and is fatal if untreated. Treated VL patients can
relapse and suffer from postkala-azar dermal leishmaniasis
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(PKDL), which is a reservoir for the emergence of drug
resistance.2,10
There is currently no approved vaccine against Leishmania
infections in humans;5 thus, the control of the disease relies on
a limited number of drug treatments that all suffer from a
number of inadequacies including cost, long-term and painful
modes of administration, toxicity, and the emergence of relapse
and resistance.11−13 When one considers this, there is an
urgent need for novel antileishmanial treatments that are
inexpensive and free of side effects.
New treatments require new modes of actions, and the
differences in essential sphingolipid synthesis offer oppor-
tunities for selective intervention in parasite metabolism. In
contrast to mammalian cells, where the predominant complex
sphingolipid is sphingomyelin (SM), Leishmania, as well as
fungi, plants, and some other protozoa, synthesize inositol
phosphorylceramide (IPC).14−18 The final step in the
synthesis, catalyzed by sphingolipid synthases (SLS), involves
the conversion of ceramides (phytoceramides in plants and
fungi) to phosphosphingolipids via the addition of a headgroup
that varies according to the substrate used. Mammals
predominantly incorporate phosphocholine from the lipid
phosphatidylcholine (PC) to generate SM species through the
action of sphingomyelin synthase (SMS) while plants, fungi,
and kinetoplastid parasites mainly use phosphatidylinositol
(PI) in a reaction catalyzed by inositol phosphorylceramide
synthase (IPCS). This divergence enabled the identification
and validation of the fungal IPC synthase (AUR1p) as a drug
target for pathogenic fungi.19−23 Subsequently, work in our
group identified and isolated the orthologous Leishmania
enzyme from L. major (LmjIPCS).24−26 Using a microsomal
preparation derived from a LmjIPCS-complemented Saccha-
romyces cerevisiae lacking the fungal AUR1p, we were able to
develop a microtiter plate-compatible assay of enzyme activity
and use this to confirm the mechanism of action and identify
critical substrate parameters.27 With this resource in hand, we
sought to identify potential inhibitors of the enzyme.
In this report, we describe the further application of this
assay to screen a set of pharmacologically active compounds
and to use the most active and selective of the hits, clemastine
fumarate 1, to chemically validate IPCS as an antileishmanial
drug target both in vitro and in vivo.
■ RESULTS
Using the previously reported microtiter plate assay,26 a diverse
set of 1040 pharmacologically active compounds (National
Institute of Neurological Disorders and Stroke [NINDS]
(NINDS set))28 were screened initially at 20 μM for activity
against LmjIPCS (Figures 1 and S1 and Table S1). Fifty-seven
compounds were found to exhibit ≥70% inhibition of the
enzyme; these were tested for efficacy against L. major
proliferative, insect stage promastigotes at 10 μM using a
resazurin-based cell-viability assay29,30 (Figure S2). While the
majority of the compounds inhibited parasite growth at 24 h
(data not shown), the extension of the assay duration to 72 h
revealed a smaller set of 16 active compounds (Figures 1, 2,
and S2 and Table S1).
Using commercially sourced samples, secondary dose
response assays for these 16 compounds were then undertaken
against L. major (FV1) promastigotes and LmjIPCS (Figures 1,
2, and S2 and Table S1). While LmjIPCS inhibition was
confirmed for amlodipine 2, chlorpromazine 3, clomiphene 4,
doxepin 5, fendiline 6, flunarizine 7, pimozide 10,
prochlorperazine edisylate 11, propranolol 12, sertraline 13,
suloctidil 15, and trifluoperazine 16, these compounds
displayed low to moderate (EC50 > 1 μM) activity against
the L. major promastigotes and were not further explored.
Pentamidine 9 is a clinically utilized antileishmanial, and this
study revealed an unexpected alternative mode-of-action to
that previously reported.31,32 IC50 values against LmjIPCS
could not be determined for pararosaniline 8 and sulfamethi-
zole 14, which also exhibited poor antileishmanial activity, and
these were also discarded.
This left clemastine fumarate 1, which demonstrated potent
activity against LmjIPCS (IC50 = 2.90 μM) and submicromolar
inhibition of promastigote proliferation (EC50 = 0.18 μM). In a
Figure 1. Schematic flowchart of the high-throughput screening
workflow. LmjIPCS-inositol phosphorylceramide synthase from
L. major.
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subsequent experiment utilizing L. major (JISH118) infected
bone marrow derived macrophages (BMDMs), this compound
demonstrated activity against intramacrophage amastigote
L. major (EC50 = 3.16 μM) and a selectivity index of 6.05
(BMDM CC50 = 19.13 μM) (Figure 3A and Table S1). The
fact that the compound demonstrated higher activity against
the axenic L. major (EC50 = 0.18 μM) than the IPCS target
(IC50 = 2.90 μM) initially appeared counterintuitive. However,
the enzyme material extracted from yeast is highly concen-
trated and, assuming cellular equivalence, estimated to be
∼100-fold greater than that present in the promastigote cell
assay. Therefore, while other modes of action were not
discounted at this stage, clemastine fumarate 1 was selected as
the most interesting hit from the NINDS library screen and
advanced to further explore the inhibition of IPCS as a viable
antileishmanial drug strategy.
Clemastine Fumarate Shows Activity against a Wide
Range of Leishmania Species. The results presented thus
far revealed the potential of clemastine fumarate 1 as an
antileishmanial drug with a novel mode-of-action (LmjIPCS
inhibition). L. major is classified as an Old World species,
prevalent in the Eastern hemisphere, and manifests as CL, the
most common form of the disease.33 However, given the global
reach of leishmaniasis, the ideal drug is one that is active
against all pathogenic species of Leishmania and therefore has
the potential to treat all forms of the disease. To explore this
possibility, clemastine fumarate was also tested against
promastigote forms of L. amazonensis, which causes New
World CL in the Western hemisphere,34 and L. infantum and
L. donovani, which both manifest as VL, the most fatal form of
the disease.33
Clemastine fumarate showed significant levels of activity
against all species of Leishmania promastigote forms tested.
EC50 [μM] values are as follows: L. major (JISH118), 0.179 ±
0.047; L. amazonensis (Josefa), 0.028 ± 0.012; L. donovani
(LV1), 0.019 ± 0.043; L. infantum (MAP263), 0.708 ± 0.043
(Figure 3B−D). Selecting L. amazonensis due to its sensitivity
to clemastine fumarate and relevance to many cases of CL and
MCL in South America, we then confirmed intramacrophage
amastigote activity. This assay revealed that clemastine
fumarate exhibits submicromolar inhibition of L. amazonensis
amastigote intramacrophage growth (EC50 = 0.462 ± 0.100
μM) and a promising selectivity index of 39.49 (CC50 BMDM
= 18.25 ± 0.05 μM) (Figure 3B).
Figure 2. NINDS library hit compounds selected for further study.
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Clemastine Fumarate Activity Is Correlated with
Inositol Phosphorylceramide Synthase Inhibition.
Coupled with the well-documented in vivo safety profile of
clemastine fumarate 135,36 [oral LD50 values of 730 mg.kg
−1
(mouse) and 3550 mg.kg−1 (rat), low toxicity against human
liver HepG2 cells (CC50 > 50 μM), and low cardiotoxicity],
the observed potency against both promastigote and, the more
clinically relevant, intramacrophage amastigote life stages
suggested that clemastine fumarate 1 had significant potential
to be employed as an antileishmanial chemotherapeutic. In
order to establish whether the antileishmanial action of
clemastine fumarate 1 occurred via its activity as an inhibitor
of the Leishmania IPCS, experiments were conducted with the
sphingolipid-free L. major mutant created through the targeted
deletion of the catalytic subunit (LmjLCB2) of the first enzyme
in the pathway, serine palmitoyltransferase.37 While these
parasites (ΔLmjLCB2) contain a functional IPCS, the lack of
de novo synthesized ceramide renders this activity redundant.37
Notably, it has been demonstrated that L. major ΔLmjLCB2
parasites maintain high levels of IPCS activity during animal
infection and, furthermore, it is known that LCB2 and serine
palmitoyltransferase activity is downregulated in pathogenic
amastigotes forms, which scavenge host ceramide to enable
IPC synthesis.38,39 In these experiments, as a control, we used
an “add-back” cell line in which the ΔLmjLCB2 mutant was
“rescued” by the expression of LmjLCB2 from a plasmid
[pXNEO LmLCB2] to generate a line in which ceramide and
IPC synthesis is restored.37 Dose−response assays for
clemastine fumarate 1 against L. major wild type promasti-
gotes, ΔLmjLCB2 mutant, and add-back (AB) lines revealed
that the EC50 of clemastine fumarate 1 against ΔLmjLCB2
parasites was 0.45 ± 0.07 μM, a significantly lower efficacy to
that observed for wild type L. major in this assay (0.16 ± 0.02
μM; Figure 4). Furthermore, the restoration of sphingolipid
biosynthesis in the add-back line restored the sensitivity of the
mutant parasites to clemastine fumarate 1 (EC50 = 0.08 ± 0.01
μM). The reasons for the increased sensitivity of the AB lines
remain unclear, although the overexpression of LmjLCB2 in
these mutant parasites37 may lead to other changes in
sphingolipid biosynthesis. Importantly, the positive control,
Figure 3. Clemastine fumarate broad range antileishmanial activity. Dose−response curves of clemastine fumarate plotting the percentage of
macrophage, intracellular amastigote, and promastigote growth inhibition for L. major (A) and L. amazonensis (B). Dose−response curves of
clemastine fumarate against L. donovani (C) and L. infantum (D) promastigotes; each curve shows a representative experiment of at least three
biological replicates. For each species, amphotericin B was used as a positive control (EC50 = 0.027 ± 0.003 μM). EC50 and CC50 values are the
mean ±95% CI from at least three experiments. SI, selectivity index (macrophage CC50/amastigote EC50).
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cycloheximide, which acts by a different mode-of-action,
maintained an EC50 value of 0.02 μM against all three parasite
lines tested. Collectively, these results supported the
hypothesis that the inhibition of IPCS is a key component of
the antileishmanial activity of clemastine fumarate 1.
To further verify this effect, a study of the effect of
clemastine fumarate 1 on the sphingolipid pathway was
initiated. Initially, we examined the phospholipid components
of the reaction catalyzed by IPCS. Targeted phospholipid
analysis by direct infusion ESI-MS/MS provided the initial
indication that parasites treated with nonlethal levels of
clemastine fumarate compound had a decreased ratio of IPC
relative to PI compared to the untreated control samples
(Figure S4). This was confirmed by GC-MS inositol
quantification of these two phospholipid pools (IPC and PI).
Encouraged by these data, we then undertook a broader
investigation of the effects of clemastine fumarate 1 (10 μM for
12 h) on the sphingolipid biosynthetic pathway in L. major
promastigotes using untargeted LC-MS metabolomics and
lipidomics. Consistent with inhibition of IPCS, these analyses
confirmed a remarkable increase in the relative abundance of
ceramide, alongside other intermediates linked to the pathway
(1.15- to 2.17-fold, P < 0.05), demonstrating significant
disruption of this metabolic pathway (Figure 5).
Selection for Clemastine Fumarate Resistance and
Cross Resistance against Other Antileishmanials. Two
individual clones of the L. major promastigote form of the
parasites (cl.C and cl.D) selected in vitro for resistance to
clemastine fumarate 1 showed EC50 values 2.5- to 3-fold
greater than the parental wild type (Figures 6 and S3).
Importantly, no evidence for cross-resistance against the front-
line antileishmanials (pentamidine, amphotericin B, miltefo-
sine, paromomycin, and the antimonials) was observed in these
parasite populations (Figure 6), indicating a different mode-of-
action or mode-of-resistance. Interestingly, the selection for
resistance to clemastine fumarate 1 in vitro generated mutants
with variants (SNPs) within the coding sequence (CDS) and
the untranslated region (UTRs) in eight genes of the
sphingolipid pathway in L. major (Table 1 and Figure S5),
consistent with the changes observed in the abundance of
intermediates involved in sphingolipid metabolism after
exposure to clemastine fumarate 1 (Figure 6). Clone cl.C
showed the higher number of SNPs (18 compared to 12 in
cl.D), including the only four found within the CDS of the
genes (Figure 6). The majority of mutations were found in the
UTRs (14 and 12, respectively), perhaps indicating that these
affect regulatory elements such as noncoding RNAs present in
these regions in Leishmania.41 Notably, in Leishmania and
other kinetoplastids, UTRs are involved in transcription and
gene expression;42,43 therefore, these mutations could
influence enzyme content. The total number of variants
identified is provided (Table S3), and the high number of
SNPs found across the genomes of the selected clones (cl.C
and cl.D compared with parental wild type) complicates our
interpretation of these polymorphisms. However, changes in
copy number (CNVs) were also observed in a number of
chromosomes from cl.C and cl.D. Of those encoding proteins
involved in sphingolipid biosynthesis, the copy numbers of
chromosomes 31 and 34 were increased in clone cl.D, while a
reduction of chromosome 8 was observed for both clones
(Table 1 and Figure S6). Table S4 provides the CNV values in
all chromosomes in both clones. Chromosomes 31 and 34
harbor the genes encoding ceramide synthase (CerS) and
serine palmitoyltransferase (SPT) subunit 2 (LCB2), respec-
tively, with amplification perhaps influencing the expression
level, sphingolipid content, and sensitivity to clemastine
fumarate 1. Chromosome 8, whose decrease in copy number
was common to both clones, harbors inositol phosphosphin-
golipid phospholipase C (ISCL). Interestingly, the loss of ISCL
has previously been demonstrated to lead to the accumulation
of IPC, indicating that a reduction in copy number may be
directly linked to clemastine fumarate 1 resistance in both
selected clones.39
Clemastine Fumarate Stimulates a Macrophage
Response to Leishmania Infection. The host response to
Leishmania infection is driven by macrophage activity that
proceeds via two major mechanisms involving either the
generation of reactive oxygen and nitrogen species (ROS/
RNS), which combine with nitric oxide (NO) to generate
peroxynitrites, powerful oxidants capable of killing micro-
organisms,44 or the formation of the acidified phagolysosome,
which rapidly kills and degrades the pathogen.45 Leishmania
spp. amastigotes have adapted to survive in macrophage
phagolysosomes by disrupting the generation of ROS.
However, in order to differentiate into amastigotes, the
promastigotes must first survive antimicrobial activities of the
macrophages. A mechanism used to achieve this involves the
inhibition of phagolysosome biogenesis.46 This leads to a
decrease in NADPH oxidase complex activity and reduces
exposure to ROS. In addition, the inhibition of phagosome
maturation excludes the vesicular proto-ATPase (v-ATPase),
required for phagosomal acidification and, consequently,
microbicidal properties of the phagosomes are impaired.
Clemastine fumarate has been reported to affect host immune
responses, and it was therefore of interest to see if these effects
were contributing to the observed antiparasitic effect.47
It was postulated that clemastine fumarate 1 could increase
NO synthesis and, consequently, peroxynitrite levels, leading
to enhanced parasite death,48 so uninfected macrophages were
treated with serial dilutions of clemastine fumarate 1 and
incubated for 48 h. Subsequently, supernatants were treated
with the Griess reagent, and the absorbance at 570 nm was
Figure 4. Clemastine fumarate antileishmanial activity is correlated
with IPCS inhibition. Promastigotes of L. major wild type (WT),
sphingolipid-free mutant (ΔLCB2), or the add-back (AB) line were
incubated with serial dilutions of clemastine fumarate for 48 h. Then,
parasite viability was assessed fluorometrically by the addition of
resazurin solution to the culture. Clemastine fumarate EC50 values are
the mean of at least three biological replicates with standard error
(bars). Statistically significant values in relation to WT (one-way
ANOVA, P < 0.05, 95% confidence interval) are shown with stars:
**P ≤ 0.01; ***P ≤ 0.001.
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measured to quantify nitrite formation. However, no significant
effect was observed, suggesting that the enhancement of NO
levels is not a contributing factor to the observed antiparasitic
activity of clemastine fumarate 1 (Figure S7).
Clemastine fumarate 1 has been shown to stimulate the
P2X7 receptor (P2X7R) which, upon activation by extrac-
ellular ATP, leads to the secretion of pro-inflammatory
cytokines and the production of ROS/RNS.49 Significantly,
macrophages infected with L. amazonensis display an enhanced
expression of P2X7R and are significantly more responsive to
extracellular ATP.50,51 Collectively, this suggested that the
enhancement of P2X7R, resulting from the treatment with
clemastine fumarate 1, could contribute to the elimination of
the parasites.52 To explore this idea, antiamastigote assays were
performed with macrophages from C57BL/6 wild type mice
and from C57BL/6 mice in which P2X7R had been knocked
out (P2X7R KO) (Figure 7). This study revealed that
clemastine fumarate 1 is >4 times more active against infected
Figure 5. Relative abundance of metabolites (LCMS) in wild type L. major promastigotes treated with clemastine fumarate (10 μM) for 12 h.
Treated (WTTx) and untreated parasites (WTCx) (x-axis) were analyzed in four biological replicates. Multivariate data analysis was performed
with PiMP pipeline.40 The Benjamini-Hochberg procedure adjusted raw P-values (q-values) < 0.05 for ANOVA. Differences among samples
(WTTx vs WTCx) were evaluated using one-way ANOVA with the Dunnett’s multiple comparison test P-value < 0.05 with the Prism software
version 8. Statistically significant values (P < 0.05, 95% confidence interval) are shown with stars: ns, nonsignificant; *P ≤ 0.05; **P ≤ 0.01; ***P
≤ 0.001; ****P ≤ 0.0001). Changes in other ceramide species are provided in Table S2.
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wild type cells when a low concentration of extracellular ATP
(100 μM) is added. In contrast, a similar experiment with
P2X7R KO macrophages did not show any effect on the
addition of extracellular ATP. This suggested that wild type
infected cells treated with clemastine fumarate 1 have an
enhanced P2X7R activity, which is responsive to low
concentrations of extracellular ATP with a downstream impact
on intracellular parasite viability.
Clemastine Fumarate Is an Effective Antileishmanial
Agent In Vivo. Once we demonstrated that clemastine
fumarate 1 was effective against Leishmania promastigotes and
intramacrophage amastigotes, with a good safety profile against
host cell macrophages, it was necessary to confirm the activity
in an animal model. On the basis of the reported safety profile
for clemastine fumarate in a mouse and the high activity
against L. amazonensis, we opted to explore in vivo efficacy
using BALB/c mice infected with L. amazonensis expressing
green fluorescent protein (GFP). For this CL model, using the
classical antimonial drug glucantime as a reference, animals
were divided into five groups comprising clemastine fumarate 1
(oral, 134 mg kg−1, five times a week); clemastine fumarate 1
(intraperitoneal [IP], 11.65 mg kg−1, twice a week); clemastine
fumarate 1 (intralesional [IL], 1.17 mg kg−1, twice a week);
glucantime (IL, 1.30 g kg−1, twice a week); untreated. Mice
were treated for 28 days, and lesion size was measured
regularly to monitor the progression of the disease. On day 41,
Figure 6. Cross resistance (EC50) against known antileishmanials of cloned clemastine fumarate-resistant L. major promastigotes. CLE, clemastine
fumarate; PENT, pentamidine; AmB, amphotericin B; MF, miltefosine; PAR, paromomycin; PAT, potassium antimony tartrate. EC50 values are the
mean of at least three biological replicates with standard error (bars). Statistically significant values (one-way ANOVAs with the Dunnett’s multiple
comparison test, P-value < 0.05, were processed with Prism software version 8, P < 0.05, 95% confidence interval) are shown with stars: ns,
nonsignificant; *P ≤ 0.05; **P ≤ 0.01.
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the animals were euthanized and parasite load was quantified
using the limiting dilution assay (LDA). There was a significant
reduction in lesion size in all clemastine fumarate-treated mice
at day 35 postinfection when compared with the untreated
control group (Figure 8A,C). All clemastine fumarate 1
treatments led to a statistically significant reduction in parasite
burden as determined by LDA (Figure 8B). Pleasingly,
clemastine fumarate administered via IP decreased the parasite
burden to a greater extent than IL glucantime, even using
lower concentrations of active compound (5.83 mM
clemastine fumarate versus 819 mM glucantime [221 mM
pentavalent antimonial]).
■ DISCUSSION
Given the cost for discovering and developing a NCE drug is
estimated at ∼$1 billion (US) and development can take up to
20 years,53 it is not surprising that the repurposing of existing
medications to treat NTDs has become a popular strat-
egy.54−56 Indeed, many of the currently used antileishmanials
were initially developed for other applications; e.g., amphoter-
icin B, a repurposed antifungal treatment;57 paromomycin, a
broad spectrum antibiotic;58 miltefosine, a failed antineoplastic
agent.59 However, all of the current therapies have difficulties
in cost, efficacy, resistance, or the mode-of-administration, and
there is a pressing need for new therapies that address these
Table 1. Genomic Changes Identified in Genes Encoding Sphingolipid Biosynthetic Enzymes in the Clemastine Fumarate
Resistance (CleR) to the Leishmania major Promastigote Form of the Parasitesa
genes encoding sphingolipid synthetic enzymes in L. major single nucleotide polymorphisms (SNPs) copy number variations (CNVs)
num. gene ID abbreviation cl.C cl.D total Chr. cl.C cl.D
1 LmjF.34.3740 SPT 1 3 4 34 increase
2 LmjF.35.0320 SPT-like 3 3 35
3 LmjF.35.0330 3-KSR 1 1 35
4 LmjF.31.1780 CerS 31 increase
5 LmjF.26.1670/80 CerD 1 1 2 26
6 Nd CerAse
7 LmjF.35.4990 IPCS 2 2 35
8 LmjF.08.0200 ISCL 2 2 8 decrease decrease
9 Nd CerK
10 Nd CerP
11 LmjF.26.0710 SK (2*) 2 4 26
12 LmjF.32.2290 S1PAse 2 (1*) 3 6 32
13 LmjF.30.2350 S1PLY 30
14 LmjF.18.0440 PAF 3 (1*) 2 6 18




aMissense (nonsynonymous) single nucleotide polymorphisms (SNPs) are indicated with a star (*); other SNPs correspond to intergenic region
variants or UTRs. Genes IDs are from the TritrypDB (https://tritrypdb.org/). SPT: serine palmitoyltransferase; 3-KSR: 3-dehydrosphinganine
reductase; CerS: ceramide synthase; CerD: sphingolipid 4-desaturase; CerA: ceramidase; IPCS: inositol phosphorylceramide synthase; ISCL:
inositol phosphosphingolipid phospholipase C; CerK: ceramide kinase; CerP: ceramide phosphatase; SK: sphingosine kinase; S1PAse: sphingosine-
1-phosphate phosphatase; S1PLY: sphingosine 1-phosphate lyase; PAF: phosphatidic acid phosphatase. Nd: nondetermined. Copy number
variations (CNVs) are indicated. πChromosomes are those not known to contain genes encoding sphingolipid biosynthetic enzymes.
Figure 7. Host cell antileishmanial activity modulation by clemastine fumarate. BMDM from C57BL/6 mice wild type (WT) or knockout for P2X7
receptor (KO) were infected with promastigotes of L. amazonensis. After 24 h of infection, cells were treated with serial dilutions of clemastine
fumarate in the presence or absence of ATP (100 μM) for 48 h at 37 °C. Cells were stained with Giemsa stain, and the number of intracellular
amastigotes in 200 macrophages was quantified by light microscopy. Clemastine fumarate EC50 values are the mean of one biological replicate with
standard error (bars). Statistically significant values in relation to WT (one-way ANOVA, P < 0.05, 95% confidence interval) are shown with stars:
ns, nonsignificant; ***P ≤ 0.001).
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issues and are amenable for the application against the diverse
variety of species that cause leishmaniasis.
In this respect, the identification of clemastine fumarate as
an effective antileishmanial in an in vivo mouse model of
infection is a significant starting point. Clemastine fumarate is
an orally available antihistamine used for the treatment of
allergic rhinitis, marketed under the brand name Tavegil,
which functions as an antagonist for the histamine H1
receptor.60 This over-the-counter drug has a well-established
safety profile,36 with the major side effects being sedation,
dizziness, disturbed coordination, epigastric distress, and dry
mouth.61 As a licensed medicine, clemastine fumarate has
proven pharmacokinetic exposure and the high volume of
distribution (9.5 ± 3.8 L kg−1) could be contributing to the
enhanced perfusion of parasite infected cells. As such, it is
perhaps not surprising that clemastine fumarate has been
identified in other repurposing studies for NTDs,62−68
including those looking for new antileishmanial applications.69
However, significant antiparasitic activity has not been
reported nor has a putative mode-of-action been identified.
The discovery of antileishmanial efficacy as a selective inhibitor
of the parasite enzyme (IPCS) that catalyzes the formation of
the primary complex sphingolipid in Leishmania spp. is exciting
given that this activity is not found in the host. Sphingolipid
biosynthesis is generally highly conserved across the Eukaryota
and has, therefore, been rarely explored in the search for new
therapeutic targets.17,18 A number of studies have explored the
various enzymes in the pathway with most effort concentrated
on the initial enzyme, serine palmitoyltransferase (SPT), as
well as the kinases and lyases that generate and degrade the key
signaling molecules, sphingosine-1-phosphate and ceramide-1-
phosphate.16 However, possibly reflecting the fact that being
membrane bound they are more difficult to study, many of the
intermediate enzymes in the pathway remain to be fully
explored.
The validation of the fungal IPCS (AUR1p) as a drug target
by workers at Upjohn was an important landmark that has
been largely overlooked by the pharmaceutical industry.21,70−72
Since then, studies have shown that other orthologues may be
targeted in mammals (sphingomyelin synthase; SMS), plants,
and protozoa.17,18 However, a viable drug acting in this fashion
has yet to be identified. The higher efficacy observed for
clemastine fumarate 1 against wild type (WT) L. major when
compared to the ΔLmjLCB2 mutant, where LmjIPCS is
redundant, is consistent with this mode-of-action, an
observation further supported by metabolomic and lipidomic
data, which showed that the addition of the compound led to
enhanced levels of ceramide and its biosynthetic precursors.
These data provided chemical validation of IPCS as an
antileishmanial target.
In this study, clemastine fumarate was identified from a
screen of a diverse set of bioactive compounds (National
Institute of Neurological Disorders and Stroke [NINDS] of
1040 compounds) for inhibitors of LmjIPCS. While we
identified 14 with micromolar activity against the enzyme,
which also had activity against L. major promastigote parasites,
the structural diversity within the set challenged the establish-
ment of any significant SAR. However, consistent with a
common therapeutic target, it is interesting to note that many
of these compounds have some structural similarity, in that
they contain both an aryl-rich portion and an amine moiety,
connected via an aliphatic linker. Significantly, the poly-
Figure 8. Efficacy of clemastine fumarate in L. amazonensis-infected mice. BALB/c mice were infected with 2 × 106 L. amazonensis GFP
promastigotes in the right ear. Seven days after the infection, mice were treated for 28 days with clemastine fumarate by the oral route (134 mg
kg−1, five times a week), the intraperitoneal route (IP; 11.65 mg kg−1, twice a week), or intralesional injections (IL; 1.17 mg kg−1, twice a week);
glucantime by the intraperitoneal route (IP; 1.30 g kg−1, twice a week); or left without treatment (UNT). Mice were euthanized seven days after
the end of treatment. (A) Lesion thickness throughout treatment. (B) Ear parasite loads on day 41 post-infection. (C) Representative photographs
of the infected ear for each group. Data are the mean of two biological replicates (n = 5) with the standard deviation. Statistically significant values
in relation to the untreated group (one-way ANOVA or two-way ANOVA, P < 0.05, 95% confidence interval) are shown with stars: *P < 0.05, **P
< 0.01, and ***P < 0.001.
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pharmacology apparent in clemastine fumarate, is not
unexpected for such basic and relatively lipophilic compounds.
One of the 14 compounds was the known antileishmanial drug
pentamidine 9, with the data shedding light on a possible new
mode-of-action, and four exhibited greater antiparasitic efficacy
than this. Interestingly, these four compounds were found to
have higher potency against the parasite than the LmjIPCS
enzyme in our assays. This may reflect pleiotropism, a
possibility supported by the fact that pentamidine 9 also
displayed a lower EC50 value against L. major promastigotes
than its IC50 value against LmjIPCS and has additional known
modes of action including the inhibition of polyamine
biosynthesis and uptake73 and DNA binding.74 Importantly,
although parasite populations showing low levels of resistance
to clemastine fumarate could be generated, no evidence for
cross resistance against the front-line antileishmanials (pen-
tamidine, amphotericin B, miltefosine, paromomycin, and the
antimonials) was observed. Again, while the low level of
resistance could, in part, be attributed to the effects of
polypharmacology exhibited by clemastine fumarate, the
genomic analyses of these resistant lines showed strong
support for changes in sphingolipid metabolism. Interestingly,
both clemastine fumarate-resistant clones tested demonstrated
statistically significant hypersensitivity to pentamidine 9
(Figure 6). While this suggested that the antileishmanial
mode-of-action for clemastine fumarate 1 and pentamidine 9 is
not the same, these data are consistent with a common
biosynthetic pathway (e.g., sphingolipid metabolism) being
affected.
Importantly, given the broad spectrum of Leishmania spp.
associated with the disease and the challenges in diagnosing
the specific species causing a given infection, the ideal drug will
act against multiple species, both Old and New World. As
such, clemastine fumarate 1 was tested against the insect stage
promastigote form of L. amazonesis, L. donovani, L. infantum,
and L. major, with the greatest activity observed against Old
World L. donovani and New World L. amazonesis (EC50 against
promastigote forms of <20 nM). The subsequent in vivo
assessment using a mouse model of L. amazonesis CL
demonstrated that IP delivered clemastine fumarate 1
outperformed the currently used antimonial glucantime.
Surprisingly, the IL dose of clemastine fumarate was less
effective than the IP dose. The reasons for this are not obvious,
but potentially, the kinetics of dosing, with IP delivery
providing a longer, slower delivery of the active agent, may
have accounted for this observation. As a repurposed drug, it is
not surprising that clemastine fumarate 1 exhibits other effects,
with the IP treated mice showing evidence of drowsiness, a
common and known side effect of clemastine fumarate 1. The
beneficial immunostimulatory effect observed on P2X7
receptors is further evidence that the in vivo antileishmanial
activity observed with clemastine fumarate arises from multiple
pathways. Whether this effect is independent or linked to
disruption of the IPCS activity and sphingolipid signaling
remains to be established. While no significant effect on NO
levels could be observed, the possibility for clemastine
fumarate to directly interact with other ROS or RNS species
cannot be disregarded.
In contrast to IP treatment, the oral treatment was only
partially effective in reducing the parasite load and promoting
somnolence (Figure S8), although it is pertinent to note that
the dose used is approximately 3× lower than the equivalent
recommended human oral dose.75 Improved formulation or
dosing regimens to increase absorption and achieve blood
concentrations equivalent to that found in humans will
possibly demonstrate the usefulness of clemastine in oral
leishmaniasis treatment.
In conclusion, this study has chemically validated IPCS as a
viable target for antileishmanial chemotherapy and identified a
safe over-the-counter drug, clemastine fumarate, as a potential
candidate for drug repurposing. IPCS inhibition therefore
represents a much needed new antileishmanial drug strategy
that exploits a distinct difference between the parasite and host
and enables the development of better drugs for this important
neglected disease. Although complete clearance of parasitaemia
was not observed with clemastine fumarate, such a sterile cure
in the BALB/C mouse model is seldom achieved,76,77 and the
results obtained with this marketed drug are exciting. Current
efforts are focused on enhancing the formulation and exploring
combination therapies to provide a higher level of in vivo
efficacy to enable future human trials.
■ METHODS
Materials. Biological grade materials, solvents, reagents,
and media components were purchased from commercial
suppliers and used as provided. L-α-Phosphatidylinositol
(bovine liver PI; predominant species 1-stearoyl-2-arachido-
noyl-sn-glycero-3-phospho-1-myo-inositol sodium salt) was
from Avanti Polar Lipids. NBD-C6-ceramide and BODIPY
FL C5-ceramide complexed to BSA were from Invitrogen. AG
4-X4 ion-exchange resin was obtained from Bio-Rad. Yeast
nitrogen base was from Invitrogen. Protease inhibitor,
Complete EDTA-free Protease Inhibitor Cocktail Tablets
were from Roche Applied Science. Amino acids drop-out
packages were from Clontech. Acid-washed glass beads (212−
300 μm) were obtained from Sigma-Aldrich. Clemastine
fumarate, amphotericin B, and compounds 2−16 were
purchased from Sigma-Aldrich and used as supplied.
Glucantime solution (meglumine antimoniate, 300 mg
mL−1) was a gift from Sanofi Aventis. The protein assay kit
was from BioRad using Coomassie Brilliant Blue G-250.
Reactions and media were prepared using high purity
distilled, deionized water. All other solvents used were of the
highest purity available commercially. The solutions of the test
compounds were made up in DMSO, unless otherwise stated.
Animals and Ethics Statement. All mice used in the
experiments were maintained under a controlled temperature,
filtered air and water, autoclave bedding, and commercial food
at the animal facilities at Federal University of Rio de Janeiro.
The animal protocols for this study were approved by the
Federal University of Rio de Janeiro Institutional Animal Care
and Use Committee under the number 030/17. The research
was conducted in compliance with the principles stated in the
Guide for the Care and Use of Laboratory Animals (NIH).78
Mice were euthanized by an overdose of isoflurane inhalation
followed by cervical dislocation.
Preparation of the LmjIPCS Enriched Microsomal
Membrane Fraction. Auxotrophic AUR1 mutant S. cerevisiae
was complemented by the expression of the L. major IPCS to
create YPH499-HIS-GAL-AUR1 pRS246 LmjIPCS. All the
steps required to obtain yeast extraction and enrich the fraction
containing microsomal membranes were performed as
described by Mina et al.26 These steps were carried out
under nonsterile conditions.
Determination of Protein Activity in Units (U). To
standardize the assay and remove variability from the sample
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preparation, microsome samples were normalized with respect
to active enzyme content. Enzymatic activity was measured in
enzyme units (U), where 1 U of enzyme is defined as that
which converts 1 pmol of substrate per minute under the
conditions described (i.e., 1 U = 1 pmol(product) min−1).
A stock solution of NBD-C6-ceramide at a concentration of
100 μM was used to create a standard curve ranging from 0.2
to 80 pmol. The volumes were adjusted to 200 μL with 1 M
potassium formate in MeOH, and the fluorescence was
measured (Ex460/Em540).
Samples of the washed microsomal membranes were
incubated with NBD-C6-ceramide and phosphatidylinositol
(PI) under assay conditions, and the product fluorescence was
measured. Correlation with the standard curve allowed the
activity of the microsome preparation to be calculated in U
μL−1. The membranes were adjusted to 1.5 U μL−1 with
storage buffer and stored in LoBind Eppendorf tubes at −80
°C.
HPTLC NBD-C6-Ceramide Fluorescence Assay.
26 Ten
mM PI in CHCl3 (1 μL) was dried into a LoBind Eppendorf
tube using a vacuum concentrator (Eppendorf Concentrator
5301). To the dried PI, Tris/EDTA/BSA buffer (20 μL) was
added, and the solution was mixed by vortexing. The volume
was adjusted to 48 μL with distilled H2O, followed by the
addition of test compound (0.5 μL) and 100 μM NBD-C6-
ceramide in DMSO (1 μL). The reaction was started by the
addition of microsomal membranes (1.5 U·μL−1, 0.5 μL), and
the mixture was incubated at 30 °C for 25 min. After
quenching with CHCl3/MeOH/H2O (10:10:3, 150 μL), the
mixture was centrifuged (14 400g, RT, 5 min) to separate
phases and the organic layer was removed. The aqueous phase
was then re-extracted with 50 μL of chloroform. The combined
organic extracts were dried in a rotavapor (Eppendorf
Concentrator 5301) and resuspended in 20 μL of chloro-
form/methanol:/water (10:10:3). 5−10 μL of the reaction
products was loaded onto an HTPLC plate, and the lipid
components were separated using the solvent system CHCl3/
MeOH/0.25% KCl(aq.) (55:45:10). The Rf values for the
substrate NBD-C6-ceramide and the product NBD-C6-IPC
were 0.96 and 0.57, respectively. Product quantification was
carried out using a fluorescence plate reader (Fujifilm,
FLA3000) (Ex473/Em520) and AIDA Image Analyzer
software (version 3.52).
96-Well Plate NBD-C6-Ceramide Fluorescence Assay.
For each 96-well assay plate, in a 10 mL vial, 48 μL of PI (10
mM in CHCl3) was dried using rotary evaporator at RT for 20
min. To the dried PI, 120 μL of NBD-C6-ceramide (200 μM in
DMSO), 480 μL of CHAPS (3 mM), and 1680 μL of assay
buffer (PO4 buffer 71.9 mM) were added. The mixture was
vortexed briefly, and 19 μL was added to each well of a 96-well
V-bottom assay plate followed by the addition of 0.8 μL
control/test compound (in DMSO); the assay plate was kept
at 4 °C.
To another 10 mL vial, 1680 μL of assay buffer, 480 μL of
CHAPS, 192 μL of storage buffer, and 48 μL of microsomal
material (0.5−0.6 U CHAPS-washed membranes) were mixed
and kept on ice. Twenty μL/well of this mixture was added to
the assay plates.
The assay was started by moving to an incubator, and the
assay plate was incubated at 30 °C for 25 min. The reaction
was quenched with 200 μL of MeOH (HPLC grade).
The filter plates were prepared briefly by suspending 10 mg
of AG4-X4 resin in 50 mL of EtOH (100%) in a 50 mL falcon
tube and were added to the filter plates as 2× additions of 100
μL/well. The filter plates were centrifuged to remove the
solvent; 50 μL of formic acid was added to each well, and the
wells were incubated for 5 min and then centrifuged to remove
the liquid phase. The plates were washed with 100 μL of dH2O
and centrifuged to remove the liquid phase.
230 μL of assay reaction mixture was loaded onto the filter
plates, and the plates were centrifuged to remove the liquid
phase followed by washing 5× with 200 μL of MeOH. The
collection plate was removed, and a new plate was used. The
product, NBD-C6-IPC, was eluted 4× with 50 μL of MeOH.
The collection plate was read at Ex480/Em540 using a
fluorescent plate reader (Synergy HT BioTek). The assays
were carried out in triplicate; data were analyzed and IC50
values were calculated using sigmoidal regression analysis
(GraphPad Prism).
Leishmania Culture. L. major (MHOM/IL/81/Friedlin;
FV1 strain [wild type, WT; add-back, AB; serine palmitoyl-
transferase mutant, ΔLmLCB2]), L. major (MHOM/SA/85/
JISH118), L. amazonensis (MHOM/BR/75/Josefa; WT and
GFP),79 L. infantum (MHOM/MA67ITMAP263), and
L. donovani (MHOM/ET/67/HU3/LV9) promastigotes
were maintained at 26 °C in Schneider’s insect medium (pH
7) or M199 medium, supplemented with 15% heat-inactivated
fetal bovine serum (FBS), 100 μg mL−1 streptomycin, and 100
IU mL−1 penicillin. L. major (FV1) AB and L. amazonensis-
GFP promastigotes were cultivated under antibiotic pressure
G418 (Gibco) at 40 or 1000 μg mL−1, respectively.
Antipromastigote Assay. L. major WT, AB, ΔLmLCB2
(4 × 105 or 1 × 106 mL−1), L. amazonensis (5 × 105 mL−1),
L. donovani (2 × 106 mL−1), and L. infantum (2 × 106 mL−1)
promastigotes were incubated in sterile 96-well plates with
compounds in triplicate (amphotericin B was used as a positive
control and untreated parasites with DMSO, as a negative
control) at 26 °C during 48 h for L. major (FV1) and 72 h for
L. major (JISH118) and all other Leishmania species. Resazurin
solution (10 μL) was then added and the plate, incubated at 26
°C for 4 h prior to measurement using a fluorescence plate
reader (Ex555/Em585). EC50 values were calculated using
sigmoidal regression analysis (GraphPad Prism).
Isolation of Bone Marrow Derived Macrophages.
Bone marrow derived macrophages (BMDMs) were differ-
entiated from bone marrow of BALB/c, C57BL/6, and knock
out C57BL/6 mice using L929-cell conditioned medium
(LCCM) as a source of macrophage colony-stimulating factor
(M-CSF) as described by Marim et al.80
Antiamastigote Intramacrophage Assay. BMDM from
BALB/c mice were diluted in RPMI 1640 medium
(supplemented with 200 mM L-glutamine, 16.5 mM
NaHCO3, and 10% FBS) to a concentration of 4 × 10
5
mL−1 in a 24-well plate with round coverslips and incubated
for 24 h at 37 °C and 5% CO2. Then, macrophages were
infected with L. major (JISH118) (7:1) or L. amazonensis
(10:1) promastigotes at 34 °C for 4 h, and noninternalized
parasites were removed by washing. After 24 h of infection,
serial dilutions of the test compounds in medium were added
and the slides were incubated at 37 °C and 5% CO2 for 5 days
(L. major) or 2 days (L. amazonensis). Amphotericin B and
miltefosine were used as controls. At the end, cells were fixed
with methanol and stained with Giemsa solution, and the
intracelular amastigotes were counted using a light microscope.
Results were expressed as the percentage reduction of
intracellular amastigotes (compared with untreated control
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wells). EC50 values were calculated using sigmoidal regression
analysis (GraphPad Prism).
Macrophage Cytotoxicity Assay. BMDMs (1 × 106
mL−1) were seeded in sterile 96-well plates in RPMI 1640
medium and incubated for 24 h at 37 °C and 5% CO2.
Following removal of the media, serial dilutions of the test
compounds in fresh medium (200 μL) were added and the
plate was incubated for 24 or 48 h at 37 °C and 5% CO2.
Resazurin solution (10 μL) was added to the wells, and cell-
viability measurements were carried out using a fluorescence
plate reader (Ex555/Em585). Podophyllotoxin or Triton X-
100 were used as a reference compound. CC50 values were
calculated using sigmoidal regression analysis (GraphPad
Prism).
Nitric Oxide Assay. BMDM uninfected macrophages (1 ×
106 mL−1, 100 μL well−1) in 96-well plates were incubated for
24 h at 37 °C and 5% CO2. Following removal of the media,
serial dilutions of the test compounds in fresh RPMI medium
(100 μL) were added and the plate was incubated for 48 h at
37 °C and 5% CO2. The release of nitric oxide was measured
in the culture supernatant by the Griess method, as described
previously.81 The absorbance was measured at 570 nm, and the
nitrite concentration was determined using a standard curve of
sodium nitrite (0 to 50 μM). The positive control was
macrophages incubated with 1 μg mL−1 LPS (Sigma-Aldrich,
Brazil) and 10% conditioned medium of lymphocytes as a
source of IFN. Negative controls were cells treated with
DMSO and untreated cells.
Antiamastigote Activity in P2X7R−/− Macrophages.
BMDMs from wild type (WT) and P2X7R−/− C57BL/6 mice
(4 × 105 mL−1) were plated in 24-well plates with round
coverslips (BMDM) and incubated for 24 h at 37 °C and 5%
CO2. Then, macrophages were infected with L. amazonensis
(10:1) promastigotes at 34 °C for 4 h. After 24 h of infection,
cells were incubated with serial dilutions of clemastine in the
presence or absence of 100 μM ATP in RPMI medium for 48
h at 37 °C and 5% CO2. At the end, cells were fixed with
methanol and stained with Giemsa solution, and the
intracelular amastigotes were counted using a light microscope.
IC50 values were calculated using sigmoidal regression analysis
(GraphPad Prism).
Phospholipid ESI-MS/MS Analysis. Leishmania major
FV1 cells, both treated with clemastine (3× biological
replicates) and untreated controls (3× biological replicates),
were extracted in chloroform/methanol/water (2:2:1; V/V)82
and, following phase separation, the organic layer was
subjected to ESI-MS/MS analysis. Organic phases were
suspended in a 1:1 ratio of 2:1 methanol/chloroform and
6:7:2 acetonitrile/isopropanol/water for direct infusion using
an Advion TriVersa NanoMate interface (∼125 nL/min) to
deliver samples to an AB Sciex 4000 QTRAP. Samples were
analyzed in negative ion mode using a capillary voltage of 1.25
kV. MS/MS scanning (precursors of m/z 241 for inositol-
phosphate containing lipids) was performed using nitrogen as
the collision gas, with collision energies between 35 and 55 V.
Each spectrum encompasses at least 30 repetitive scans.
Phospholipid species annotations were determined in reference
to previous assignments83 and the LIPID MAPS database.
GC-MS Quantitative Inositol Phospholipid Analysis.
Relative amounts of myo-inositol containing lipids (IPC and
PI) were quantified, and the means of three separate analyses
were determined for IPC and PI inositol quantification. Briefly,
lipid samples underwent base hydrolysis: treatment with 500
μL of 50% concentrated ammonia and 50% propan-1-ol (1:1),
followed by incubation for at least 5 h at 50 °C. Upon drying
under nitrogen and removal of traces of ammonia with 2
rounds of H2O/MeOH evaporation, samples were suspended
in chloroform/methanol/water (2:2:1; V/V) in order to
separate (organic phase) IPC from inositol-phospho-glycerol
derived from hydrolyzed PI species (aqueous phase). These
two phases were dried and processed for GC-MS inositol
content determination as described previously.83
Selection for Clemastine Resistance. Two independent
lines of L. major (FV1) were selected for resistance against
clemastine over 5 months by increasing the concentration of
drug in the culture medium in a stepwise manner. The parental
wild type was also cultured in parallel in the absence of drug.
Individual clones were then selected from each resistant line by
limiting dilution.
Whole Genome Sequencing. WGS was performed for
the two clones to investigate if resistance to clemastine
fumarate was associated with genomic changes. Reads of 2 ×
75 bp paired-end sequencing were obtained at Glasgow
Polyomics using an Illumina NextSeq500 sequencer. The
reference genomes and gene annotation of L. major strain
Friedlin was obtained from TriTrypDB release 46 (http://
tritrypdb.org). Reads were mapped to the reference genomes
using BWA-MEM.84 PCR duplicates were removed using
GATK (version 4.1.4.1).85 Variants that exist in resistant
strains but not in parental wild type strains were identified
using MuTect (version 1.1.7)86 and MuTect287 with the
default settings. The effects of the variants were predicted
using snpEff software.88 Copy ratio alterations were detected
using GATK (version 4.1.8.1). Reference genomes were
divided into equally sized bins of 1000 base pairs using
PreprocessIntervals tool. Read counts in each bin were
collected from alignment data using CollectReadCounts tool.
Copy ratios of a resistant sample over a matched non-resistant
sample were obtained from read counts using CreateRead-
CountPanelOfNormals and DenoiseReadCounts tools. Ge-
nome contigs were segmented using ModelSegments tool from
copy ratios of resistant and non-resistant samples. Amplified
and deleted segments were identified using CallCopyRatioSeg-
ments tool with the default settings. Plots of denoised and
segmented copy-ratios were generated using PlotModeledSeg-
ments tool. Sequencing raw data was deposited at the
European Nucleotide Archive (ENA) under project number
PRJNA665266.
LC/MS Metabolomics and Lipidomics Analysis.
Metabolite Extraction. Time-to-kill and dose-to-kill were
determined (Table S5), and L. major (FV1) promastigotes
were treated with high concentrations of clemastine for 12 h or
left untreated as the control condition. At the 12 h exposure
time point, metabolites were extracted (1 × 107 cells per
sample, 4× biological replicates per condition) using an
MTBE/methanol/water procedure for biphasic extraction.89
The aqueous phase from each sample was subjected to
metabolomics analysis and the organic phase, to lipidomics
analysis.
Metabolomic Analysis. Samples were analyzed at Glasgow
Polyomics using liquid chromatography−mass spectrometry
(LC-MS) as previously described.90 Briefly, hydrophilic
interaction liquid chromatography (HILIC) was performed
using a Dionex UltiMate 3000 RSLC system (Thermo Fisher
Scientific, Hemel Hempstead, UK) using a ZIC-pHILIC
column (150 mm × 4.6 mm, 5 μm column, Merck Sequant).
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The column was maintained at 30 °C, and samples were eluted
with a linear gradient using the solvent system: (A) 20 mM
ammonium carbonate in water and (B) acetonitrile over 26
min (flow rate of 0.3 mL/min). Samples were injected (10 μL)
and were maintained at 5 °C prior to injection. MS analysis
was performed using a Thermo Orbitrap Fusion (Thermo
Fisher Scientific) operated in polarity switching mode
(resolution = 120 000; AGC = 2 × 105; m/z = 70−1000;
sheath gas = 40; auxiliary gas = 5; sweep gas = 1; probe
temperature = 150 °C; capillary temperature = 325 °C). For
positive mode ionization, the source voltage was +4.3 kV; for
negative mode ionization, the source voltage was −3.2 kV, and
S-lens RF level was 60%. Pooled samples were employed for
quality control purposes to assess the reproducibility of the
instrument, being analyzed at 5-sample intervals throughout
the run.
Lipidomics Analysis. Lipidomics sample analysis at Glasgow
Polyomics was conducted in a similar way to metabolomics
analysis with adjustments made to coincide with previously
described HILIC lipidomics methodology.91 Adjustments were
as follows: an ACE unbonded silica column (150 mm × 3.0
mm, 3 μm column, Advanced Chromatography Technologies)
was used; samples were eluted using the solvent system: (A)
20% isopropanol and 80% acetonitrile and (B) 20%
isopropanol with 20 mM ammonium formate in water over
40 min.
Data Analysis. Both metabolomics and lipidomics data was
analyzed using the PiMP analysis pipeline for data filtering and
metabolite annotation.40 Except in instances where metabolite
retention times matched those of the authentic standards
(Level 1 assignments), annotated metabolite identities are
assigned at Level 2 in accordance with Metabolomics
Standards Initiative directives.92
Antileishmanial Efficacy In Vivo. BALB/c female mice
were infected in the right ear with 2 × 106 promastigotes of
L. amazonensis-GFP. Seven days after the infection, animals
were randomly distributed into 5 groups and treated for 28
days with clemastine by oral the route (134 mg kg−1, five times
a week), by the intraperitoneal route (11.65 mg kg−1, twice a
week), or by subcutaneous injections (1.17 mg kg−1, twice a
week). OraPlus (Perrigo) was used as a vehicle for clemastine
oral formulation while PBS was the vehicle for the other routes.
Glucantime was given by the intraperitoneal route (1.30 g
kg−1, twice a week), as a reference drug, and the untreated
group as the negative control. Infected ear thicknesses were
measured once or twice a week with a calliper gauge, and the
lesion sizes were expressed as the difference between the
thickness of the infected and noninfected ear. On day 41 post-
infection, the animals were euthanized and the parasite loads in
the individual lesions were quantified using a limiting dilution
assay (LDA).93 Pictures of each lesion were taken at the end of
the treatment.
Behavioral Analyses. BALB/c female mice received a
single dose of clemastine by oral (134 mg kg−1) and
intraperitoneal (11.65 mg kg−1) routes or each respective
vehicle, OraPlus or PBS. Five minutes after treatment, mice
exploratory capacity was carried out in an open field arena
measuring 0.3 × 0.3 × 0.45 m3, as described previously.94 In
each box, one animal was allowed to freely move for 30 min,
and the total distance was recorded and quantified using the
ANY-maze software (Stoelting Co.). The experiment was
performed twice using two animals per group.
Statistical Analysis. Data were analyzed by one-way or
two-way ANOVA followed by Dunnett’s multiple comparison
test. Data were expressed as arithmetic mean ± standard
deviation (SD) values, and samples were considered
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